基本信息:
- 专利标题： 表达CXCL10和CCL21趋化因子靶向嵌合抗原受体T淋巴细胞的构建方法及应用
- 专利标题（英）：Construction method and application of targeting chimeric antigen receptor T lymphocyte for expressing CXCL10 and CCL21 chemotactic factors
- 申请号：CN201810812992.6 申请日：2018-07-23
- 公开(公告)号：CN108949692A 公开(公告)日：2018-12-07
- 发明人： 吴斌 , 王维 , 刘振云 , 程丰伟 , 韩江萌
- 申请人： 安徽古一生物科技有限公司
- 申请人地址： 安徽省合肥市巢湖市经济开发区管委会南三楼301室
- 专利权人： 安徽古一生物科技有限公司
- 当前专利权人： 苏州一兮生物技术有限公司
- 当前专利权人地址： 安徽省合肥市巢湖市经济开发区管委会南三楼301室
- 代理机构： 合肥市浩智运专利代理事务所
- 代理人： 王志兴
- 主分类号： C12N5/10
- IPC分类号： C12N5/10 ; C12N15/85 ; C12N15/62 ; A61K35/17 ; A61P35/00
The invention provides a construction method of a targeting chimeric antigen receptor T lymphocyte for expressing CXCL10 and CCL21 chemotactic factors. The method comprises the following steps: sequence selection: constructing a pCDH carrier containing a chimeric antigen receptor; cloning DNA of CXCL10 and CCL21 into the pCDH carrier containing the chimeric antigen receptor; and slow virus packaging: preparing the targeting chimeric antigen receptor T lymphocyte for expressing the CXCL10 and CCL21 chemotactic factors. The invention further provides an application of the chimeric antigen receptor T lymphocyte in the treatment of solid tumor immunotherapy. According to the construction method, a tumor specific antigen is taken as a target spot and is applied to the auxiliary expression of CXCL10 and CCL21 molecules, so that the targeting effect on tumor cells can be realized, the tumor angiogenesis can be inhibited, the blood supply of tumor tissues is reduced, a solid tumor is killed toan extreme extend, and the new breakthrough on the immunotherapy of the solid tumor is realized.
公开/授权文献:
- CN108949692B 表达CXCL10和CCL21趋化因子靶向嵌合抗原受体T淋巴细胞的构建方法及应用 公开/授权日：2021-08-13